The TLC-ART team continues to advance long-acting, synchronized drug-combination therapy across HIV, anti-infective, and cancer research. Recent publications from the team and collaborators highlight progress in long-acting HIV injectable products, global access strategies for generic long-acting antiretrovirals, regulatory classification of long-acting parenteral products, and drug-combination nanoparticle approaches for cancer therapy.<\/p>\n
A novel all-in-one injectable composed of tenofovir alafenamide\u2013dolutegravir\u2013lamivudine exhibits long-acting plasma and cell drug persistence for 8 weeks<\/strong><\/p>\n Stephen ZR, Perazzolo S, Duan L, Eguchi M, et al. This study reports a 3-in-1 long-acting injectable product composed of tenofovir alafenamide, dolutegravir, and lamivudine. The formulation is built on the drug-combination nanoparticle platform and was evaluated in juvenile nonhuman primates. The study showed long-acting plasma and cellular drug persistence for up to 8 weeks, supporting the potential of an all-in-one injectable HIV treatment approach.<\/p>\n Classification System Proposed to Guide the Design, Development, Regulatory Approval, and Scaling of Long-Acting, Small- and Macro-Molecule Parenteral Products (CS-BLAP)<\/strong><\/p>\n Perazzolo S, Shen DD, Ho RJY. This article proposes CS-BLAP, a classification framework for long-acting parenteral products. The system is designed to guide product design, development, regulatory evaluation, and post-approval scaling. CS-BLAP distinguishes long-acting products based on product size, absorption route, lymphatic versus blood uptake, and whether the product is a small molecule or macromolecule.<\/p>\n Drug Combination Nanoparticles Containing Gemcitabine and Paclitaxel Enable Orthotopic 4T1 Breast Tumor Regression<\/strong><\/p>\n Yu J, Xu X, Griffin JI, Mu Q, Ho RJY. This study evaluated gemcitabine\u2013paclitaxel drug-combination nanoparticles in an orthotopic 4T1 breast tumor model. The formulation enabled synchronized drug delivery and produced substantially greater tumor suppression than equivalent free-drug combination treatment, supporting the broader application of the DcNP platform in cancer therapy.<\/p>\n Inoculation of Pan02 Cells Produces Tumor Nodules in Mouse Pancreas: Characterization of a Novel Orthotopic Pancreatic Ductal Adenocarcinoma Tumor Model for Interventional Studies<\/strong><\/p>\n Griffin JI, Chen X, Duan L, Mu Q, Ho RJY. This work describes a reproducible orthotopic pancreatic ductal adenocarcinoma model using intraperitoneal inoculation of Pan02 cells in mice. The model produces pancreatic tumor nodules without surgical implantation, providing a practical preclinical platform for evaluating pancreatic cancer treatment candidates.<\/p>\n Novel Drug Combination Nanoparticles Exhibit Enhanced Plasma Exposure and Dose-Responsive Effects on Eliminating Breast Cancer Lung Metastasis<\/strong><\/p>\n Mu Q, Yu J, Griffin JI, Wu Y, Zhu L, McConnachie LA, Ho RJY. This study demonstrated that gemcitabine\u2013paclitaxel drug-combination nanoparticles increased drug exposure and showed dose-responsive activity against breast cancer lung metastasis in a mouse model. The findings support the DcNP platform as a scalable approach for improving combination chemotherapy delivery.<\/p>\n TLC-ART develops targeted, long-acting, synchronized drug-combination therapies designed to improve drug exposure at relevant tissues and cells while reducing limitations associated with conventional dosing. The program applies drug-combination nanoparticle technologies across HIV, anti-infective, and cancer applications.<\/p>\n
\nAIDS<\/em>. 2026.
\nPMID: 42084126. DOI: 10.1097\/QAD.0000000000004531.
\nView on PubMed \u2192<\/a><\/p>\nCS-BLAP: classification system for long-acting parenteral products<\/h3>\n
\nJournal of Pharmaceutical Sciences<\/em>. 2026;115(2):104056.
\nPMID: 41205697. DOI: 10.1016\/j.xphs.2025.104056.
\nView on PubMed \u2192<\/a><\/p>\n
\nDrug-combination nanoparticles for orthotopic breast tumor regression<\/h3>\n
\nCancers<\/em>. 2024;16:2792.
\nDOI: 10.3390\/cancers16162792.
\nView publication \u2192<\/a><\/p>\n
\nOrthotopic Pan02 pancreatic tumor model<\/h3>\n
\nPLOS ONE<\/em>. 2024;19(3):e0300723.
\nDOI: 10.1371\/journal.pone.0300723.
\nView publication \u2192<\/a><\/p>\n
\nDrug-combination nanoparticles for metastatic breast cancer<\/h3>\n
\nPLOS ONE<\/em>. 2020;15(3):e0228557.
\nDOI: 10.1371\/journal.pone.0228557.
\nView publication \u2192<\/a><\/p>\n
\nAbout TLC-ART<\/h2>\n